Generic Anoro Ellipta Availability
Last updated on Aug 6, 2025.
Anoro Ellipta is a brand name of umeclidinium/vilanterol, approved by the FDA in the following formulation(s):
ANORO ELLIPTA (umeclidinium bromide; vilanterol trifenatate - powder;inhalation)
-
Manufacturer: GLAXOSMITHKLINE
Approval date: December 18, 2013
Strength(s): EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH [RLD]
Is there a generic version of Anoro Ellipta available?
An Authorized Generic version of Anoro Ellipta has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance and has exactly the same inactive ingredients.
List of authorized generic versions:
- umeclidinium bromide and vilanterol trifenatate RESPIRATORY (INHALATION) POWDER 62.5; 25 ug/1; ug
Prasco Laboratories
NDC Code: 669930134
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Anoro Ellipta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Patent 11,090,294
Issued: August 17, 2021
Inventor(s): Baker; Darrell et al.
Assignee(s): Glaxo Group Limited (Middlesex, GB)Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.
Patent expiration dates:
- November 29, 2030✓
- November 29, 2030
-
Phenethanolamine derivatives for treatment of respiratory diseases
Patent 7,439,393
Issued: October 21, 2008
Inventor(s): Box; Philip Charles et al.
Assignee(s): Glaxo Group Limited (Greenford, Middlesex, GB)The invention relates to 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyet- hyl}-2-(hydroxymethyl)phenol; and salts and solvates thereof, including those which are pharmaceutically acceptable, along with formulations thereof, combinations thereof, and methods for the treatment or prophylaxis of mammals by administering such compounds.
Patent expiration dates:
- May 21, 2025✓✓✓
- May 21, 2025
-
Phenethanolamine derivatives for treatment of respiratory diseases
Patent 7439393*PED
Issued: October 21, 2008
Inventor(s): Box; Philip Charles et al.
Assignee(s): Glaxo Group Limited (Greenford, Middlesex, GB)The invention relates to 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyet- hyl}-2-(hydroxymethyl)phenol; and salts and solvates thereof, including those which are pharmaceutically acceptable, along with formulations thereof, combinations thereof, and methods for the treatment or prophylaxis of mammals by administering such compounds.
Patent expiration dates:
- November 21, 2025✓
- November 21, 2025
-
Muscarinic acetylcholine receptor antagonists
Patent 7,488,827
Issued: February 10, 2009
Inventor(s): Laine; Damane I. et al.
Assignee(s): Glaxo Group Limited (Greenford, Middlesex, GB)Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
Patent expiration dates:
- December 18, 2027✓✓
- December 18, 2027
-
Muscarinic acetylcholine receptor antagonists
Patent 7,498,440
Issued: March 3, 2009
Inventor(s): Laine; Damane I. et al.
Assignee(s): Glaxo Group Limited (Greenford, Middlesex, GB)Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
Patent expiration dates:
- April 27, 2025✓✓
- April 27, 2025
-
Muscarinic acetylcholine receptor antagonists
Patent 8,183,257
Issued: May 22, 2012
Inventor(s): Laine Dramane I. & Palovich Michael R. & McCleland Brent W. & Neipp Christopher E. & Thomas Sonia M.
Assignee(s): Glaxo Group LimitedMuscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
Patent expiration dates:
- July 27, 2025✓
- July 27, 2025
-
Muscarinic acetylcholine receptor antagonists
Patent 8,309,572
Issued: November 13, 2012
Inventor(s): Laine Dramane I. & Palovich Michael R. & McCleland Brent W. & Neipp Christopher E. & Thomas Sonia M.
Assignee(s): Glaxo Group LimitedMuscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
Patent expiration dates:
- April 27, 2025✓
- April 27, 2025
-
Medicament dispenser
Patent 8,511,304
Issued: August 20, 2013
Inventor(s): Anderson Gregor John McLennan & Bonney Stanley George & Davies Michael Birsha & Lintell Daniel Thomas De Sansmarez & Wilson Alan Anthony
Assignee(s): Glaxo Group LimitedThere is provided a medicament dispenser for use with plural elongate form medicament carriers, each having multiple distinct medicament dose portions carried thereby, the dispenser having a dispensing mechanism for dispensing the distinct medicament dose portions carried by each of the plural medicament carriers. The mechanism comprises a receiving station for receiving each of the plural medicament carriers; a release for releasing a distinct medicament dose portion from each of the plural medicament carriers on receipt thereof by the receiving station; an outlet, positioned to be in communication with the distinct medicament dose portions releasable by said a release; and an indexer for individually indexing the distinct medicament dose portions of each of the plural medicament carriers.
Patent expiration dates:
- June 14, 2027✓✓
- June 14, 2027
-
Medicament dispenser
Patent 8511304*PED
Issued: August 20, 2013
Inventor(s): Anderson Gregor John McLennan & Bonney Stanley George & Davies Michael Birsha & Lintell Daniel Thomas De Sansmarez & Wilson Alan Anthony
Assignee(s): Glaxo Group LimitedThere is provided a medicament dispenser for use with plural elongate form medicament carriers, each having multiple distinct medicament dose portions carried thereby, the dispenser having a dispensing mechanism for dispensing the distinct medicament dose portions carried by each of the plural medicament carriers. The mechanism comprises a receiving station for receiving each of the plural medicament carriers; a release for releasing a distinct medicament dose portion from each of the plural medicament carriers on receipt thereof by the receiving station; an outlet, positioned to be in communication with the distinct medicament dose portions releasable by said a release; and an indexer for individually indexing the distinct medicament dose portions of each of the plural medicament carriers.
Patent expiration dates:
- December 14, 2027✓
- December 14, 2027
-
Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Patent 9,750,726
Issued: September 5, 2017
Inventor(s): Baker Darrell & Bruce Mark & Crater Glenn & Noga Brian & Thomas Marian & Wire Patrick
Assignee(s): Glaxo Group LimitedCombinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.
Patent expiration dates:
- November 29, 2030✓
- November 29, 2030
More about Anoro Ellipta (umeclidinium / vilanterol)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (70)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: bronchodilator combinations
- En español
Patient resources
Professional resources
- Anoro Ellipta prescribing information
- Umeclidinium and Vilanterol (Oral Inhalation) (AHFS Monograph)
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.